The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications.
about
Statin use and Parkinson's disease in Denmark.Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease.Naturopathic medicine and type 2 diabetes: a retrospective analysis from an academic clinicIs statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations.Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms.Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics.Considerations for supplementing with coenzyme Q10 during statin therapy.Should we lower cholesterol as much as possible?Statins and memory loss: An Australian experienceBeneficial Effects of Coenzyme Q10 Supplementation on Lipid Profile and Intereukin-6 and Intercellular Adhesion Molecule-1 Reduction, Preliminary Results of a Double-blind Trial in Acute Myocardial InfarctionMitochondria-Fundamental to Life and Health.The "Mevalonate hypothesis": a cholesterol-independent alternative for the etiology of atherosclerosis.Simvastatin-induced cognitive dysfunction: two case reportsStatin use and the risk of Parkinson diseaseBioenergetic and antioxidant properties of coenzyme Q10: recent developments.Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts.Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet.Cellular factories for coenzyme Q10 production.Is there a place for coenzyme Q in the management of metabolic disorders associated with obesity?Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.Strategies for oral delivery and mitochondrial targeting of CoQ10.Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats.Effects of coenzyme q10 supplementation on serum lipoproteins, plasma fibrinogen, and blood pressure in patients with hyperlipidemia and myocardial infarction.Statins and modulation of oxidative stress.Kenyan purple tea anthocyanins ability to cross the blood brain barrier and reinforce brain antioxidant capacity in mice.[Lipid lowering drug and other toxic myopathies].A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics.Cholesterol Metabolism in T Cells.Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin.Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats.
P2860
Q34020626-0C51A98D-468E-4243-A945-A2A5B97818A9Q34098304-9860AF66-8BF5-4242-A8B0-8044636D9C17Q34146656-72389680-EB8C-4F5C-BA4C-AA883B8A5B6CQ34219598-C55EC892-E6FC-4E88-95F1-0B6E3F97D384Q34461476-E5638171-F761-4281-B468-4BE3EB4FF829Q34503981-56ECFC04-129A-4A26-8CA1-BD735D0BD1ACQ34564606-832041D6-E16E-485D-80E2-4C4D26839469Q34654691-8B8887BE-CF2B-464D-B752-232674044168Q35273182-93190B9C-C095-4B59-9EB1-0DEC03A6D393Q35973462-573D4F77-F1A6-4B1D-ABFD-BF6954823188Q36384427-51DD7890-4A3A-438C-BAD5-53D5BECA64CEQ36394541-74C13D91-6ACF-4716-9230-1B49B8A595D1Q36769580-163C8674-D6FD-4B06-AE1D-160146FCDB4AQ36948690-114E27A1-0723-4351-8565-82CC0397DAC4Q36959666-0F918C8F-DFED-4908-A17D-02796DD24155Q37424595-F9FC4733-5FC0-4ABF-947F-71246758129AQ37535770-110EDB39-08E9-458F-BE8A-5A607BC55B78Q37679098-67255024-A0D6-4631-A462-1573A1A046EEQ38056543-2001027A-DED7-4AFD-8797-FD888AE42026Q38179262-38547DE4-FC42-4EA7-9F70-971BC0F2654EQ38301993-B1F098D2-670A-461C-B84A-15B30E475B8DQ39474081-C415AF40-8D70-4188-B074-AD727D7FDC0AQ43148428-7EC8F7FD-87C6-4F45-97EC-1FC3FC0A263BQ43215640-E8DFBA31-CD79-4D0B-8D4E-FF855B421F18Q43702073-76A0D8FF-650F-4700-842C-10BE7294BC36Q46694148-E52DBD16-DE25-4293-B85F-D5CF078B69E8Q46755100-83D863BD-2ACF-4544-B198-DA6EE80B3E93Q47104177-FD37CCF3-2EF4-4659-BB59-8897E77B5B70Q47925020-C1EB2353-3F31-44AF-B3BF-5503831399D9Q50469720-47BD0269-96A4-46BA-B536-870B3232DFAE
P2860
The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The clinical use of HMG CoA-re ...... animal and human publications.
@ast
The clinical use of HMG CoA-re ...... animal and human publications.
@en
The clinical use of HMG CoA-re ...... animal and human publications.
@nl
type
label
The clinical use of HMG CoA-re ...... animal and human publications.
@ast
The clinical use of HMG CoA-re ...... animal and human publications.
@en
The clinical use of HMG CoA-re ...... animal and human publications.
@nl
prefLabel
The clinical use of HMG CoA-re ...... animal and human publications.
@ast
The clinical use of HMG CoA-re ...... animal and human publications.
@en
The clinical use of HMG CoA-re ...... animal and human publications.
@nl
P2860
P356
P1433
P1476
The clinical use of HMG CoA-re ...... animal and human publications.
@en
P2093
Alena M Langsjoen
Peter H Langsjoen
P2860
P304
P356
10.1002/BIOF.5520180212
P577
2003-01-01T00:00:00Z